

RIL/SECTL/2025/
31/05/2025

The Stock Exchange Mumbai
Corporate Relationship Dept.,
Phirozee Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Ltd
Exchange Plaza, C-1,
Block G, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 051

Scrip Code: 500367

Symbol: RUBFILA

Dear Sir,

Sub :- Submission of Newspaper Publication with respect to Audited Financial Results for the Quarter / year ended 31st March,2025- Reg.

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 please find enclosed herewith the following:-


- i) Copy of Audited Financial Results for the Quarter / year ended 31st March,2025, published by way of advertisement on 30th May,2025, in Hindu Business Line (all editions) in English and Kerala Kaumudi (Palakkad Edition) in Malayalam.

Kindly take the documents on record.

Thanking You,

Yours Truly,
For **RUBFILA INTERNATIONAL LTD**

SUDHESH
MADAYOTH

 Digitally signed by SUDHESH
MADAYOTH
Date: 2025.05.31 09:02:13 +05'30'

M SUDHESH
Asst Gen. Manager (Finance & Legal)

Encl : a/a

Glenmark in talks for licensing deal for cancer drug candidate ISB 2001

BIG MOVE. Pharma major also looking to make diabetes, weightloss drug semaglutide for India

PT Jyothi Datta
Mumbai

Glenmark Pharmaceuticals is in talks with global drug-makers for a licensing deal on its ISB 2001 drug candidate being developed for use in the treatment of multiple myeloma, top executives with the drugmaker said, outlining growth plans that included making diabetes and weightloss drug semaglutide for India.

IN DISCUSSIONS
The company is in "advanced discussions with multiple partners, all big pharma partners," Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd (GPL), told analysts, adding that a "positive outcome" could be expected soon.

"We think a deal for (ISB) 2001 will really be transformational for Glenmark. And it will overshadow anything else that we are doing in the near term... You should see some visibility around a licensing deal pretty quickly," he added.

ISB 2001 is part of the innovative pipeline of Ichnos



A deal for (ISB) 2001 will really be transformational for us... It will overshadow anything else that we are doing in the near term

GLENN SALDANHA
CMD, Glenmark Pharmaceuticals Ltd



Glenmark Innovation (IGI) — an alliance between Glenmark's US-based biotech subsidiary Ichnos Sciences and GPL — that had received the US Food and Drug Administration's fast-track designation this month, as a treatment for patients with relapsed/refractory multiple myeloma. Two of GPL's drug candidates in immunology have already been partnered out — ISB 880 and ISB 830.

Giving details on ISB 2001, a company official said that it is among the first trispecific antibodies developed for use in multiple myeloma. It received orphan drug designation from the FDA in July 2023, besides the recent fast track designation, as a treatment for patients

with relapsed refractory multiple myeloma, "specifically patients who have received 3 or more prior lines of treatment." IGI will also be presenting data on this candidate at the upcoming American Society of Clinical Oncology (ASCO) conference in a few days.

EYES OPPORTUNITY
Glenmark is also throwing its hat in the opportunity that opens up when semaglutide, the popular diabetes and weightloss product, goes off patent next year. Industry peers, including Cipla, Lupin and Mankind, have stated their intent to participate in this opportunity for the drug, popular globally by its brand name Ozempic/

Wegovy. Novo Nordisk, the maker of Wegovy (the injectible drug) is expected to bring in this product shortly. The oral version of semaglutide already sells in India.

SWISS FACILITY
Meanwhile, Glenmark pointed to IGI's announcement in March and said all its clinical supply manufacturing at its facility in La Chaux-de-Fonds, Switzerland, would cease. "As IGI is progressing its pipeline, it is anticipated that higher quantities of finished product will be required for future clinical programmes and IGI CMC (chemistry, manufacturing, and controls) development and ongoing future clinical programmes — manufacturing of ongoing clinical programmes will be moved to a network of well-established global contract development and manufacturing organisations," the representative said. The development comes 10 years after this facility was opened — to supplement Glenmark's existing in-house discovery and development capabilities by supplying material for clinical development, the company then said.

Arvind eyes ₹475 crore capex for FY26

Avinash Nair
Ahmedabad

Arvind has pledged a capital expenditure of an estimated ₹475 crore for FY26, as the company targets to ramp up its garment manufacturing capacity to 60 million garments within one-and-a-half years.

INDIA-UK FTA DEAL
The company felt that the India-UK FTA deal would help it "re-balance" its dependence on the US market.

"I think another watershed event, the signing of the FTA (Free Trade Agreement) between India and the UK is important, especially for the textile and apparel business.

"India will become an interesting sourcing destination for the UK.

And it will also benefit Arvind quite significantly in securing the right kind of rebalancing to US dependence," said Punit Lalbhai, Vice-Chairman, Arvind, during a recent earnings call.

He said that the company will use the opportunity provided by the FTA to "put more resources behind developing the UK market". Despite the uncertainties continuing to surround US tariffs, he said that there was a robust demand scenario in that country.

"We are still going to remain heavily indexed on the US, as all our customers even there are only talking about increasing business than decreasing business."

90-DAY US TARIFF-PAUSE
He added that the 90-day US

tariff-pause had led to advancement of orders. "There are a few pre-pone-ments because people want to lock-in their prices until the window of certainty exists.

So, that's leading to capacity imbalances as well. The

situation is a little chaotic compared to normal times," he said.

The company currently has an annual garment manufacturing capacity of 40 million, which is expected to be scaled up to 50 million by the current fiscal-end.

EASTERN TRENDS LIMITED					
Regd. Office: 3A, 3rd floor, Eastern Corporate Office, 34/137 E, NH Bypass, Edappally, Kochi, Ernakulam-682 024, Kerala. Phone No: 0484 7161100, email: trends@eastertreads.com Web: www.eastertreads.com, CIN: L25119KL1993PLC007213					
Extract of the Audited Financial Results for the year ended 31 st March 2025					
Sl No.	Particulars (Refer notes below)	Quarter ended		Year ended	
		31-Mar-25 Audited	31-Mar-24 Audited	31-Mar-25 Audited	31-Mar-24 Audited
1	Total Income from operations	1,600.42	1,481.70	6,062.56	5,976.84
2	(Loss)/Profit before exceptional and extraordinary items and taxes	(46.98)	(81.48)	(378.41)	(311.78)
3	(Loss)/Profit before taxes (after exceptional and extraordinary items)	(46.98)	(81.48)	(378.41)	(311.78)
4	(Loss)/Profit after taxes (after exceptional and extraordinary items)	(23.28)	(70.50)	(303.12)	(294.73)
5	Total comprehensive (loss)/profit for the period	(43.56)	(41.92)	(312.57)	(280.29)
6	Paid-up equity share capital (face value of ₹ 10 each)	523.20	523.20	523.20	523.20
7	Reserve - as shown in the Audited Balance Sheet of the previous year			(1,820.02)	(1,507.45)
8	(Loss) / Profit per equity share:				
	(1) Basic: (₹)	(0.44)	(1.35)	(5.79)	(5.63)
	(2) Diluted: (₹)	(0.44)	(1.35)	(5.79)	(5.63)

Notes:
1) The above is an extract of the detailed format of Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange website (www.bseindia.com) and on Company website (www.eastertreads.com).
2) The Financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 29th May 2025 and the audit of the same has been carried out by the statutory auditors.

Place: Kochi
Date: 29th May 2025

For EASTERN TRENDS LIMITED
M.E Mohamed
Managing Director
DIN: 00129005

Mapmygenome enters US market through acquisition of Microbiome Insights

KV Kurmanath
Hyderabad

Mapmygenome, an AI-based genomics and personalised health solutions provider, has acquired the Canadian microbial sequencing company Microbiome Insights for an undisclosed consideration.

"The acquisition gets us access to its CAP (College of American Pathologists)-accredited laboratory set up by the target company. It will help us tap the US market. We will introduce its integrated genomics and microbiome testing services to North America, making holistic, data-driven health solutions more accessible," Anu Acharya, Founder-Chief Executive Officer, told businessline.

INTERNATIONAL ACCREDITATION
Laboratories have to undergo a rigorous accreditation process by the CAP to ensure that they meet high standards in laboratory testing and operations. This accreditation is recognised internationally.

"The human microbiome is pivotal to health, and this acquisition positions us as a leader in this area. We gain exceptional expertise in metagenomics, transcriptomics and targeted metabolomics to serve academic, biotech and clinical sectors," Acharya said. "The combination of their expertise in AI-driven genomics solutions and our deep microbiome expertise will result in a new standard of cutting-edge services for clients," Malcolm Kendall, CEO, said.

AMARA RAJA ENERGY & MOBILITY LIMITED										
(Formerly known as Amara Raja Batteries Limited)										
CIN: L31402AP1985PLC005305										
Registered office: Renigunta - Cuddapah Road, Karakambadi, Tirupati - 517520, Andhra Pradesh.										
Tel: 91 (877) 2265000 Fax: 91 (877) 2285600										
E-mail id: investorservices@amararaja.com Website: www.amararajaeandm.com										
EXTRACT FROM STATEMENT OF STANDALONE AND CONSOLIDATED RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025										
Particulars	Standalone Results					Consolidated Results				
	Quarter ended		Year Ended			Quarter ended		Year Ended		
	31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024	31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
	Unaudited	Unaudited	Unaudited	Audited	Audited	Unaudited	Unaudited	Unaudited	Audited	Audited
Total revenue from operations	2,973.85	3,164.02	2,796.73	12,404.89	11,260.30	3,060.07	3,272.47	2,907.86	12,846.32	11,708.44
Net Profit for the period (before tax, Exceptional and/or Extraordinary items)	224.36	311.09	305.34	1,188.08	1,211.03	212.62	297.70	309.39	1,162.10	1,250.22
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	224.36	422.16	305.34	1,299.15	1,211.03	212.62	408.77	309.39	1,273.17	1,250.22
Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	166.81	311.83	228.03	963.90	905.86	161.57	298.37	229.78	944.67	934.38
Total comprehensive income for the period (Comprising net profit after tax and other comprehensive income/loss after tax)	58.60	180.00	223.74	799.97	899.66	53.67	166.64	225.85	780.75	928.34
Paid-up equity share capital (face value of ₹ 1/- each)	18.30	18.30	18.30	18.30	18.30	18.30	18.30	18.30	18.30	18.30
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet				7,359.97	6,750.35				7,370.83	6,780.43
Earnings per share (of ₹ 1/- each) (for the period - not annualised) Basic and Diluted (₹)	9.11	17.04	12.46	52.66	49.49	8.83	16.30	12.55	51.62	51.05

Note: The above is an extract from the Statement of Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results and notes there to are available on the stock exchange websites (www.nseindia.com and www.bseindia.com) and on Company's website i.e. www.amararajaeandm.com.

Place: Hyderabad
Date: May 29, 2025

For Amara Raja Energy & Mobility Limited
(Formerly known as Amara Raja Batteries Limited)
Jayadev Galla
DIN: 00143610 | Chairman, Managing Director & CEO

RUBFILA International Limited						
CIN L25199KL1993PLC007018						
EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2025						
STANDALONE / CONSOLIDATED RESULTS						
Sl. No.	Particulars	Standalone Results			Consolidated Results	
		Quarter ended 31.03.2025	Corresponding Quarter ended 31.03.2024	Year Ended 31.03.2025	Quarter ended 31.03.2025	Corresponding Quarter ended 31.03.2024
1.	Total Income from Operations (net)	12,697.72	10,866.04	47,323.36	14,895.38	12,988.60
2.	Net Profit / (Loss) for the period (before Tax and Exceptional Items)	1,060.25	709.92	3,345.99	1,129.01	956.41
3.	Net Profit / (Loss) for the period before Tax (after Exceptional Items)	1,060.25	709.92	3,345.99	1,129.01	956.41
4.	Net Profit / (Loss) for the period after Tax	768.51	522.42	2,464.52	830.91	709.25
5.	Total Comprehensive Income for the period (Comprising Profit & Loss for the period (after Tax) and Other Comprehensive Income (after Tax))	818.15	495.60	2,514.16	877.52	674.83
6.	Equity Share Capital (Face Value Rs.5/-)	2,713.38	2,713.38	2,713.38	2,713.38	2,713.38
7.	Other Equity	24,725.74	22,862.79	24,725.74	26,888.57	24,349.32
8.	Net Worth	27,439.12	25,576.17	27,439.12	29,401.95	27,062.70
9.	Debt Equity Ratio	0.19	0.18	0.19	0.22	0.22
10.	Earnings Per Share -EPS (of Rs.5/- each) (for Continuing operations)					
	a) Basic	1.51	0.91	4.63	1.62	1.24
	b) Diluted	1.51	0.91	4.63	1.62	1.24
11.	Capital Redemption Reserve	Nil	Nil	Nil	Nil	Nil
12.	Debt Redemption Reserve	Nil	Nil	Nil	Nil	Nil
13.	Debt Coverage ratio	NA	NA	NA	NA	NA
14.	Interest Coverage Service Ratio	NA	NA	NA	NA	NA

NOTES:
1) The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial results are available on the Websites of the Stock Exchanges and on the Company's Website (www.rubfila.com).
2) The above Audited standalone / consolidated financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular dated 5 July, 2016.
3) The Consolidated financial results of the year ended 31.03.2025 includes the financial results of its wholly owned subsidiary M/s Premier Tissues India Limited.
4) The Board of Directors of M/s. Rubfila International Ltd (the Company) have recommended a final Dividend of Rs 2/- per share amounting to Rs 1085.352 Lacs on equity share of Rs.5/- each for the year, subject to approval from shareholders.
5) The company's reportable business segments are "Latex Rubber Thread" and "Corrugated Carton Box" and its subsidiary has one reportable business segment viz "Paper Tissue".
6) The number of Investor Complaints pending at the beginning of the quarter was nil, one complaint is received and resolved during the quarter and no complaints were pending at the end of the quarter.
7) The above results were reviewed by the audit committee and approved by the Board of Directors at their respective meetings held on 28th May 2025 and the auditors have issued an unmodified opinion on the same.

For and on behalf of the Board of Directors
RUBFILA INTERNATIONAL LTD
Sd/-
G. KRISHNA KUMAR
Managing Director

Palakkad
May 28, 2025

HINDUSTAN OIL EXPLORATION COMPANY LIMITED										
Registered Office: 'HOEC House', Tandalja Road, Off Old Padra Road, Vadodara-390 020.										
Website: www.hoec.com Email: hoecshare@hoec.com CIN: L11100GJ1996PLC029880										
Extract of statement of standalone and consolidated financial results for the quarter and year ended March 31, 2025										
(₹ in Lacs except per share data)										
Sr. No.	Particulars	Standalone				Consolidated				
		Quarter ended		Year ended		Quarter ended		Year ended		
		31-Mar-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Mar-24 (Unaudited)	31-Mar-25 (Audited)	31-Mar-24 (Audited)	31-Mar-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Mar-24 (Unaudited)	31-Mar-25 (Audited)
1	Total Income from Operations	17,901.90	7,513.03	22,702.68	38,498.00	52,124.09	10,047.20	15,019.30	29,261.47	49,699.34
2	Net Profit for the period (before tax and exceptional items)	13,100.85	496.12	1,966.08	14,847.33	8,500.21	3,557.68	5,246.53	5,233.15	14,995.13
3	Net Profit for the period before tax (after exceptional items)	13,100.85	496.12	1,966.08	14,847.33	8,500.21	3,557.68	5,246.53	8,519.79	14,995.13
4	Net Profit for the period after tax (after Exceptional Items)	13,000.81	496.12	1,966.08	14,747.33	8,500.21	5,115.93	4,331.82	7,060.90	14,720.77
5	Total Comprehensive Income for the period (Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax))	12,988.97	487.70	1,934.77	14,709.19	8,466.53	5,104.83	4,323.40	7,030.47	14,684.41
6	Equity Share Capital	13,225.93	13,225.93	13,225.93	13,225.93	13,225.93	13,225.93	13,225.93	13,225.93	13,225.93
7	Reserves				1,02,712.67	88,107.72				1,18,602.96
8	Earnings Per Share (Face value of ₹ 10/-each) (not annualized)									
	Basic EPS ₹	₹ 9.83	₹ 0.38	₹ 1.49	₹ 11.15	₹ 6.43	₹ 3.87	₹ 3.28	₹ 5.34	₹ 11.13
	Diluted EPS ₹	₹ 9.83	₹ 0.38	₹ 1.49	₹ 11.15	₹ 6.43	₹ 3.87	₹ 3.28	₹ 5.34	₹ 11.13

The above is an extract of detailed format of Quarterly financial results filed with the stock exchanges under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The full format of the Quarterly financial results is available on the stock exchange websites www.bseindia.com, www.nseindia.com and Company's website www.hoec.com.

Place : Chennai
Date : May 28, 2025

BY ORDER OF THE BOARD
For Hindustan Oil Exploration Company Limited
R.Jeevanandam
Managing Director
DIN: 07046442

